226 related articles for article (PubMed ID: 10861314)
1. Rapid reporting and review of an increased incidence of a known adverse event.
Sargent DJ; Goldberg RM; Mahoney MR; Hillman DW; McKeough T; Hamilton SF; Darcy JM; Anderson VL; Krook JE; O'Connell MJ
J Natl Cancer Inst; 2000 Jun; 92(12):1011-3. PubMed ID: 10861314
[No Abstract] [Full Text] [Related]
2. SOP 09: Statistical design and analysis.
Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
[No Abstract] [Full Text] [Related]
3. Standardization, more funds on horizon for clinical trials.
McNeil C
J Natl Cancer Inst; 2005 Apr; 97(8):555-7. PubMed ID: 15840874
[No Abstract] [Full Text] [Related]
4. SOP 08: Reporting of adverse events.
Onkologie; 2003 Oct; 26 Suppl 6():41-2. PubMed ID: 23570185
[No Abstract] [Full Text] [Related]
5. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
6. Clinical trial monitoring: hit or miss?
Cohen J
Science; 1994 Jun; 264(5165):1534-7. PubMed ID: 8202707
[No Abstract] [Full Text] [Related]
7. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
Abrams JS; Mooney MM; Zwiebel JA; Korn EL; Friedman SH; Finnigan SR; Schettino PR; Denicoff AM; Kruhm MG; Montello M; Misra RR; Ansher SS; DiPiazza KJ; Souhan EM; Wickerham DL; Giantonio BJ; O'Donnell RT; Sullivan DM; Soto NI; Fleming GF; Prindiville SA; Petryshyn RA; Hautala JA; Grad O; Zuckerman BL; Meyer RM; Yao JC; Baker LA; Buckner JC; Hortobagyi GN; Doroshow JH
J Natl Cancer Inst; 2013 Jul; 105(13):954-9. PubMed ID: 23776198
[TBL] [Abstract][Full Text] [Related]
8. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
Anderson SJ
J Clin Oncol; 2006 Aug; 24(24):3821-2. PubMed ID: 16921032
[No Abstract] [Full Text] [Related]
9. Bone marrow purging, 4-hydroperoxycyclophosphamide, and the FDA.
Rowley SD
J Hematother; 1993; 2(3):289-92. PubMed ID: 7921991
[No Abstract] [Full Text] [Related]
10. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
[No Abstract] [Full Text] [Related]
11. Tighter safety controls needed over clinical trials, says FDA.
Am J Health Syst Pharm; 1995 Feb; 52(4):357. PubMed ID: 7757854
[No Abstract] [Full Text] [Related]
12. Development of rational drug combinations with investigational targeted agents.
Clark A; Ellis M; Erlichman C; Lutzker S; Zwiebel J
Oncologist; 2010; 15(5):496-9. PubMed ID: 20489187
[TBL] [Abstract][Full Text] [Related]
13. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
[TBL] [Abstract][Full Text] [Related]
14. SOP 06: Selecting the participating centers and activation of a trial.
Onkologie; 2003 Oct; 26 Suppl 6():34-5. PubMed ID: 23570182
[No Abstract] [Full Text] [Related]
15. Institutional review boards: a crisis in confidence.
Levine RJ
Ann Intern Med; 2001 Jan; 134(2):161-3. PubMed ID: 11177321
[No Abstract] [Full Text] [Related]
16. How does a drug get to phase III trials?
Reynolds T
J Natl Cancer Inst; 2000 Oct; 92(19):1555. PubMed ID: 11018084
[No Abstract] [Full Text] [Related]
17. Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research.
J Immunother; 1997 May; 20(3):214-43. PubMed ID: 9181460
[No Abstract] [Full Text] [Related]
18. Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program.
Goldberg RM; Sargent DJ; Morton RF; Mahoney MR; Krook JE; O'Connell MJ
J Clin Oncol; 2002 Dec; 20(23):4591-6. PubMed ID: 12454117
[TBL] [Abstract][Full Text] [Related]
19. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
Goldman SA
Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
[TBL] [Abstract][Full Text] [Related]
20. SOP 04: Data collection forms (case report forms).
Onkologie; 2003 Oct; 26 Suppl 6():15-22. PubMed ID: 23570180
[No Abstract] [Full Text] [Related]
[Next] [New Search]
